期刊文献+

药物洗脱支架与血管内放射治疗在支架内再狭窄中运用的Meta分析 被引量:3

Meta-analysis of drug-eluting stents implantation versus vascular brachytherapy for in-stent restenosis
原文传递
导出
摘要 目的比较药物洗脱支架与血管内放射治疗在支架内再狭窄治疗中的疗效及安全性。方法利用文献检索方法收集国内外治疗支架内再狭窄的对比研究,对符合入选条件的文献采用RevMan 5.1软件进行Meta分析。结果入选13篇文献,共纳入病例2 312例,其中药物洗脱支架组1 259例,血管内放射治疗组1 053例。Meta分析显示:药物洗脱支架组再发支架内狭窄(P<0.000 01)、晚期管腔丢失(P<0.000 01)、靶血管血运重建(P=0.03)和主要不良心血管事件(P=0.004)均明显低于血管内放射治疗组。药物洗脱支架组晚期支架血栓发生率和死亡率与血管内放射治疗组相比差异均无统计学意义。结论 Meta分析显示,药物洗脱支架治疗支架内再狭窄在降低支架再次狭窄、减少晚期管腔丢失、靶血管血运重建方面明显优于血管内放射治疗,但不能减少晚期支架血栓形成及降低患者的死亡率。 Objective To compare the efficacy and safety of drug-eluting stents (DES) implantation and vascular brachytherapy(VBT) for in-stent restenosis(ISR). Methods Controlled trials of DES versus VBT for in-stent resteno- sis were collected by literature search method and Meta-analysis was performed by using Review Manager software ver- sion 5.1. Results 13 controlled trials with 2312 patients were included. Of the 2 312 patients, 1 259 were in the DES group and 1053 were in the VBT group. Meta-analysis indicated that, the incidence of binary restenosis (P 〈 0.000 01 ), late lumen loss ( P 〈 0. 000 01 ), target-vessel revascularization (TVR) ( P = 0.03 ) and adverse cardiac e- vent (MACE) (P = 0. 004) in the DES group were significantly lower compared with those of the VBT group. There were no significant differences in the incidence and mortality of late stent thrombosis between the two groups. Conclu- sion Drug-eluting stents are markedly superior to VBT for the treatment of ISR in binary restenosis, late lumen loss, TVR reduction, but not in late stent thrombosis and mortality reduction.
出处 《山东大学学报(医学版)》 CAS 北大核心 2013年第1期56-63,共8页 Journal of Shandong University:Health Sciences
关键词 药物洗脱支架 血管内放射治疗 支架内再狭窄 META分析 Drug-eluting stents Vascular brachytherapy In-stent restenosis Meta-analysis
  • 相关文献

参考文献28

  • 1Kastrati A,Mehilli J, Dirschinger J, et al. Restenosis after coronary placement of various stent types [J]. Am J Cardiol, 2001,87( 1 ) :34-39.
  • 2Aminian A, Kabir T, Eeckhout E. Treatment of drug-eluting stent restenosis : an emerging challenge [J]. Catheter Cardiovasc Interv, 2009, 74( 1 ) :108-116.
  • 3Oliver L N, Buttner P G, Hobson H, et al. A meta-analysis of randomised controlled trials assessing drug-eluting stents and vascular brachytherapy in the treatment of coronary artery in-stent restenosis[J]. Int J Cardiol, 2008, 126(2) :216-223.
  • 4Furlan A D, Pennick V, Bombardier C, et al. 2009 updated method guidelines for systematic reviews in the Cochrane Back Review Group[J]. Spine (Phila Pa 1976), 2009, 34(18) : 1929-1941.
  • 5Zavalloni D, Belli G, Rossi M L, et al. Comparison between drug-eluting stents and beta-radiation for the treatment of diffuse in-stent restenosis: clinical and angiographic outcomes[J]. Am Heart J, 2006,152(5) :908e-908e7.
  • 6Pohl T, Kupatt C, Steinbeck G, et al. Angiographic and clinical outcome for the treatment of in-stent restenosis with sirolimus-eluting stent compared to vascular brachytherapy[J]. Z Kardiol, 2005, 94(6) :405-410.
  • 7Feres F, Munoz J S, Abizaid A, et al. Comparison between sirolimus-eluting stents and intracoronary catheter-based beta radiation for the treatment of in-stent restenosis [J]. Am J Cardiol, 2005, 96(12) : 1656-1662.
  • 8Lee S W, Park S W, Park D W, et al. Comparison of six-month angiographic and three-year outcomes after sirolimus-eluting stent implantation versus brachytherapy for bare metal in-stent restenosis [J]. Am J Cardiol, 2007, 100(3) :425-430.
  • 9Park S W, Lee S W, Koo B K, et al. Treatment of diffuse in-stent restenosis with drug-eluting stems vs. intracoronary beta-radiation therapy: INDEED Study [J]. Int J Cardiol, 2008, 131(1) :70-77.
  • 10Schukro C, Syeda B, Kirisits C, et al. Randomized comparison between intracoronary beta-radiation brachytherapy and implantation of paclitaxel-eluting stents for the treatment of diffuse in-stent restenosis [J]. Radiother Oncol, 2007, 82(1) :18-23.

二级参考文献20

  • 1Colombo A, Latib A. Treatment of drug-eluting stent restenosis with another dmg-eluting stent:do not fail the second time [ J ] ! Rev Esp Cardiol,2008,61 : 1120-1122.
  • 2Cutlip DE, Windecker S, Mehran R, et al. Clinical end points in coronary stent trails a case for standardized definitions [ J ]. Circulatlon, 2007,115 : 2344-2351.
  • 3Stone GW, Ellis SG, Stephen G, et al. Offsetting impact of thrombosis and rest- enosis on the occurrence of the death and myocardial infarction after paclitaxel-e- luting and bare metal stent implantation [ J ]. Circulation, 2007,115:2842-2847.
  • 4Stone GW, Ellis SG, Cox DA, et al. A polymer-based paclitaxel-eluting stent in patients with coronary artery disease[J]. N Engl J Med,200d-,350:221-231.
  • 5Windecker S,Serruys PW,Wandel S,et al. Biolimus-eluting stent with biode- gredable polymer versus sirohmus-eluting stent with durable polymer for coro- nary revascularisation(LEADERS) :a randomized non-inferiority trial[ J ]. Lan- cet,2008,372:1163 -1173.
  • 6Jukema JW, Verschuren JJ, Ahmed TA, et al. Restenosis after PCI. Part1 : patho- physiology and risk factors [ J ]. Nat Rev,2011,132 : 1-10.
  • 7Chen MS,John JM,Chew DP,et al. Bare metal stent restenosis is not a benign clinical entity[J]. Am Heart J,2006,151:1260-1264.
  • 8Nayak AK, Kawamura A, Nesto RW, et al. Myocardial infarction as a presenta- tion of clinical in-stent restenosis [ J ]. Circ J ,2006,70 : 1026-1029.
  • 9Yusuf RZ, Duan Z, Lamendola DE, et al. Paclitaxel resistance : molecular mecha- nisms and pharmacologic manipulation [ J ]. Curt Cancer Drug Targets, 2003,3 : 1-19.
  • 10Huang S, Houghton PJ. Mechanisms of resistance to rapamycins [ J ]. Drug Re- sist Updat,2001,4:378-391.

共引文献9

同被引文献55

  • 1杨娜,赵学忠,王全伟,田晓庆,郝守艳.冠状动脉支架内再狭窄的研究进展[J].中国老年学杂志,2014,34(6):1731-1733. 被引量:14
  • 2Pendyala L, Jabara R, Shinke T, et al. Drug-eluting stents : present and future [J]. Cardiovasc Hematol Agents Med Chem,2008,6 (2):105-115.
  • 3Kang SJ ,Mintz GS ,Park DW,et al. Mechanisms of In-Stent restenosis after drug-eluting stent implantation intravascular ultrasound analysis[J]. Circ Cardiovasc Interv, 2011,4 ( 1 ) : 9-14.
  • 4Dangas GD, Claessen BE, Caixeta AA, et al. In-Stent restenosis in the drug-eluting stem era[J]. J Am Coll Cardiol,2010,56 (23):1897-1907.
  • 5Cutlip DE, Windeeker S, Mehran R, et al. Clinical end points in coronary stent trials :a case for standardized definitions [J]. Circulation,2007, 115(17) :2344-2351.
  • 6Latib A, Mussardo M, Ielasi A, et al. Long-term outcomes after the percu- taneous treatment of drug-eluting stent restenosis[J]. JACC Cardiovase Interv, 2011,4(2) :155-164.
  • 7Maeh F. Toward new therapeutic strategies against neointimal formation in restenosis[J]. Arterioscler Thromb Vasc Biol, 2000,20 (7) : 1699-1700.
  • 8Roffman DS. Considerations in patients receiving oral antiplateIet therapy after acute coronary syndrome and percutaneous coronary intervention[J]. Am J Health Syst Pharm, 2010,67 ( 15 Suppl 7 ) : S18-24.
  • 9Daemen J, Serruys PW. Drug-eluting stent update 2007 : part I . A survey of current and future generation drug-eluting stents : meaningfuladvances or more of the same[J]. Circulation, 2007,116 (3) : 316-328.
  • 10Minha S, Pichard AD, Waksman R. In-stent restenosis of drug-eluting stents[J]. Future Cardiology, 2013,9 (5) : 721-731.

引证文献3

二级引证文献16

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部